Switch theme
Sign up to access all valuation multiples
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and, in particular, multiple myeloma.
2000
80
LTM Revenue $6.9M
LTM EBITDA -$25.6M
$37.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oncopeptides has a last 12-month revenue (LTM) of $6.9M and a last 12-month EBITDA of -$25.6M.
In the most recent fiscal year, Oncopeptides achieved revenue of $3.3M and an EBITDA of -$27.0M.
Oncopeptides expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oncopeptides valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.9M | XXX | $3.3M | XXX | XXX | XXX |
| Gross Profit | $6.5M | XXX | $3.0M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | -$25.6M | XXX | -$27.0M | XXX | XXX | XXX |
| EBITDA Margin | -368% | XXX | -827% | XXX | XXX | XXX |
| EBIT | -$25.9M | XXX | -$29.3M | XXX | XXX | XXX |
| EBIT Margin | -373% | XXX | -899% | XXX | XXX | XXX |
| Net Profit | -$24.9M | XXX | -$29.4M | XXX | XXX | XXX |
| Net Margin | -358% | XXX | -899% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oncopeptides's stock price is SEK 2 (or $0).
Oncopeptides has current market cap of SEK 350M (or $36.1M), and EV of SEK 361M (or $37.3M).
See Oncopeptides trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37.3M | $36.1M | XXX | XXX | XXX | XXX | $-0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oncopeptides has market cap of $36.1M and EV of $37.3M.
Oncopeptides's trades at 11.4x EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate Oncopeptides's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncopeptides has a P/E ratio of -1.5x.
See valuation multiples for Oncopeptides and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36.1M | XXX | $36.1M | XXX | XXX | XXX |
| EV (current) | $37.3M | XXX | $37.3M | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 11.4x | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | -1.4x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | -1.4x | XXX | -1.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOncopeptides's last 12 month revenue growth is 140%
Oncopeptides's revenue per employee in the last FY averaged $41K, while opex per employee averaged $0.4M for the same period.
Oncopeptides's rule of 40 is -518% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncopeptides's rule of X is -18% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oncopeptides and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 140% | XXX | 167% | XXX | XXX | XXX |
| EBITDA Margin | -368% | XXX | -827% | XXX | XXX | XXX |
| EBITDA Growth | -37% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -518% | XXX | -687% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -18% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $41K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 431% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 383% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 991% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncopeptides acquired XXX companies to date.
Last acquisition by Oncopeptides was XXXXXXXX, XXXXX XXXXX XXXXXX . Oncopeptides acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oncopeptides founded? | Oncopeptides was founded in 2000. |
| Where is Oncopeptides headquartered? | Oncopeptides is headquartered in Sweden. |
| How many employees does Oncopeptides have? | As of today, Oncopeptides has 80 employees. |
| Who is the CEO of Oncopeptides? | Oncopeptides's CEO is Ms. Sofia Heigis. |
| Is Oncopeptides publicy listed? | Yes, Oncopeptides is a public company listed on STO. |
| What is the stock symbol of Oncopeptides? | Oncopeptides trades under ONCO ticker. |
| When did Oncopeptides go public? | Oncopeptides went public in 2017. |
| Who are competitors of Oncopeptides? | Similar companies to Oncopeptides include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oncopeptides? | Oncopeptides's current market cap is $36.1M |
| What is the current revenue of Oncopeptides? | Oncopeptides's last 12 months revenue is $6.9M. |
| What is the current revenue growth of Oncopeptides? | Oncopeptides revenue growth (NTM/LTM) is 140%. |
| What is the current EV/Revenue multiple of Oncopeptides? | Current revenue multiple of Oncopeptides is 5.4x. |
| Is Oncopeptides profitable? | Yes, Oncopeptides is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oncopeptides? | Oncopeptides's last 12 months EBITDA is -$25.6M. |
| What is Oncopeptides's EBITDA margin? | Oncopeptides's last 12 months EBITDA margin is -368%. |
| What is the current EV/EBITDA multiple of Oncopeptides? | Current EBITDA multiple of Oncopeptides is -1.5x. |
| What is the current FCF of Oncopeptides? | Oncopeptides's last 12 months FCF is -$26.5M. |
| What is Oncopeptides's FCF margin? | Oncopeptides's last 12 months FCF margin is -381%. |
| What is the current EV/FCF multiple of Oncopeptides? | Current FCF multiple of Oncopeptides is -1.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
